• Clarithromycin as a CYP3A Inhibitor: Workflows and Troublesh

  2026-07-30

  Clarithromycin enables precision CYP3A inhibition for drug-drug interaction and pharmacokinetic studies, with robust workflows for statin metabolism and cardiovascular drug interaction research. Here, we dissect optimized protocols, troubleshooting insights, and novel applications, translating evidence into reproducible bench success.

• Dabigatran Etexilate: Advancing Oral Anticoagulation Beyond

  2026-07-30

  The reference study introduces dabigatran etexilate as the first oral direct thrombin inhibitor that circumvents the pharmacokinetic and safety limitations posed by CYP3A-mediated drug interactions. Its predictable anticoagulant effect, independence from cytochrome P450 metabolism, and suitability for stroke and VTE prevention mark a significant innovation for both clinical and drug-drug interaction research.

• Angiotensin (1-7): Mechanisms, Protocols, and Research Bench

  2026-07-29

  Angiotensin (1-7) is an endogenous heptapeptide hormone that acts as a Mas receptor agonist. It counteracts angiotensin II-mediated effects via distinct PI3K/AKT and ERK signaling, offering anti-fibrotic and anti-inflammatory actions. This dossier summarizes verified mechanisms, protocol parameters, and best practices for research use of Angiotensin (1-7).

• Metformin HCl Attenuates Vocal Fold Fibrosis via AMPK Modula

  2026-07-29

  This study demonstrates that Metformin Hydrochloride (Metformin HCl) significantly reduces vocal fold fibrosis in a rabbit injury model by activating the AMPK signaling pathway. These results provide mechanistic insight into metformin’s antifibrotic effects and suggest a potential translational strategy for managing vocal fold scarring, a condition with currently limited therapeutic options.

• FH1 Small Molecule: Optimizing iPS Hepatocyte Differentiatio

  2026-07-28

  FH1 (Catalog No. B3700) stands out for its robust enhancement of iPS cell-derived hepatocyte maturation, doubling albumin secretion and improving functional markers in culture. Explore stepwise protocols, troubleshooting, and how FH1 accelerates translational liver research and optogenetic advances.

• (S)-Mephenytoin as a CYP2C19 Substrate: Advancing In Vitro M

  2026-07-28

  (S)-Mephenytoin stands out as a gold-standard CYP2C19 substrate, enabling precise modeling of human drug metabolism in advanced in vitro systems. Leveraging APExBIO’s high-purity compound streamlines pharmacokinetic studies, particularly with hiPSC-derived intestinal organoids.

• Letrozole in Translational Research: Mechanisms and Strategy

  2026-07-27

  This thought-leadership article explores Letrozole’s mechanistic landscape as a non-steroidal aromatase inhibitor and provides strategic guidance for its optimized use in translational research. Integrating recent findings and protocol insights, it offers a critical lens on Letrozole’s role in breast cancer and neuroendocrine models, competitive context versus SERMs, and actionable paths for future research.

• Z-DEVD-FMK in Apoptosis and Lysosomal Pathways: Beyond Caspa

  2026-07-27

  Explore how Z-DEVD-FMK, a potent caspase-3 inhibitor, advances apoptosis assays and enables new strategies for studying lysosomal cell death pathways. This article uniquely bridges neuroprotection, cancer research, and the latest mechanistic insights.

• Recombinant Mouse M-CSF without Tag: Advanced Insights for M

  2026-07-26

  Explore how Recombinant Mouse Macrophage Colony Stimulating Factor (M-CSF) without Tag unlocks advanced macrophage assay design, with a focus on metabolic polarization and fibrosis modeling. This article delivers unique, practical guidance for leveraging M-CSF in translational research.

• Mechanomemory and YAP Translocation via F-actin After Interm

  2026-07-25

  This study uncovers how short, intermittent mechanical stresses induce a persistent cellular memory—mechanomemory—by increasing F-actin, which drives YAP translocation into the nucleus. The findings clarify the molecular mechanisms linking transient mechanical cues to long-term changes in gene expression, providing a foundation for future cytoskeletal and mechanotransduction research.

• Light-Inducible RNA-Releasing Proteins Enable Precise Gene R

  2026-07-24

  The referenced study introduces a rationally designed, light-inducible RNA-releasing protein (LIRP) that enables reversible, tissue-specific translational control of gene therapies in vivo. This innovation allows on-demand, optogenetic regulation of therapeutic transgenes, improving safety and temporal precision for treating metabolic and retinal diseases.

• Boc-D-FMK: Pan-Caspase Inhibitor Workflows in Apoptosis Rese

  2026-07-24

  Boc-D-FMK from APExBIO enables reproducible, high-fidelity inhibition of caspase-driven apoptosis and inflammation in cellular and animal models. This guide details optimized workflows, key troubleshooting insights, and protocol enhancements for scientists aiming to dissect cell death pathways with precision.

• Applied Strategies Using (-)-Blebbistatin for Cytoskeletal D

  2026-07-23

  (-)-Blebbistatin, a potent non-muscle myosin II inhibitor, enables precise modulation of actin-myosin interactions for advanced mechanobiology and cardiac contractility studies. This article delivers actionable workflow refinements, comparative advantages, and troubleshooting guidance, empowering researchers to extract reproducible, high-sensitivity data across cytoskeletal, cardiac, and cell migration models.

• Pandemic Box Compounds for MDR Pathogen Control: In Vitro In

  2026-07-23

  This study systematically evaluated MMV Pandemic Response Box compounds against multidrug-resistant (MDR) bacterial and fungal clinical isolates, identifying several agents with potent in vitro activity against pathogens such as A. baumannii and P. aeruginosa. The findings highlight new chemical scaffolds with promise for addressing antibiotic resistance and inform future antimicrobial development and testing workflows.

• Light-Inducible RNA-Releasing Proteins for Gene Therapy Cont

  2026-07-22

  This article examines the development of a rationally designed light-inducible RNA-releasing protein (LIRP), enabling precise, reversible control of gene translation in vivo. The approach offers new opportunities for regulated gene therapies, particularly for chronic metabolic and retinal diseases requiring on-demand transgene activity.

15762 records 1/1051 page Next 12345 下5页 Last page